Clinical and Interventional Cardiology, Sassari University Hospital, Sassari, Italy.
Department of Medicine, Surgery and Pharmacy, University and AOU of Sassari, Sassari, Italy.
Am Heart J. 2024 Dec;278:72-82. doi: 10.1016/j.ahj.2024.08.018. Epub 2024 Aug 27.
There are sex differences in HF patients. It is not clear whether such differences mainly reflect cultural behaviours and clinical inertia, and the role of sex on clinical outcomes is still controversial. We aimed to investigate the association of sex with in-hospital management and outcomes in patients with HF.
We analyzed data of 4016 adult patients hospitalized for HF in 2020 to 2021 and enrolled in a multicentre national registry.
Women (n = 1,818 [45%]) were older than men (83 vs 77 years, P < .0001), with a higher prevalence of arterial hypertension (73% vs 69%, P = .011) and atrial fibrillation. Women presented more frequently with HF and preserved ejection fraction -HFpEF (55% vs 32%, P < .001). They were more often hospitalized in internal medicine departments (71% vs 51%), and men in highly specialized cardiology units (49% vs 29%). When considering HF pharmacological treatments at discharge in the subgroup with reduced ejection fraction -HFrEF (n=1525), there were no significant differences (49% of women treated with GDMT [guideline-directed medical therapy] vs 52% of men, P = .197). Sex was not associated either with hospital readmissions (30-days OR [95% CI] = 0.89 [0.71-1.11], P = .304; 1-year OR [95% CI] = 1.02[0.88-1.19], P = .777) or with mortality (in-hospital OR [95% CI] = 1.14 [0.73-1.78], P = .558; 1-year OR [95% CI] = 1.08 [0.87-1.33], P = .478). Similar results were obtained when considering different HF categories based on left ventricular ejection fraction.
Women and men exhibited distinct clinical profiles. Although this may have had an impact on hospital pathways (noncardiology/cardiology units) and pharmacological prescriptions, sex per se did not appear as an independent determinant of clinical choices. Moreover, when considering homogeneous groups, women were not undertreated. Finally, female sex was not associated with worse clinical outcomes.
心衰患者存在性别差异。目前尚不清楚这些差异主要反映了文化行为和临床惯性,还是性别对临床结局的影响仍存在争议。我们旨在研究性别与心衰患者住院期间管理和结局的关系。
我们分析了 2020 年至 2021 年期间因心衰住院的 4016 名成年患者的数据,并纳入了一项多中心全国注册研究。
女性(n=1818[45%])比男性(83 岁比 77 岁,P<0.0001)年龄更大,动脉高血压(73%比 69%,P=0.011)和心房颤动的患病率更高。女性更常因心衰和射血分数保留的心衰-HFpEF(55%比 32%,P<0.001)住院。她们更常在内科病房(71%比 51%)住院,而男性则更常在高度专业化的心脏病学病房(49%比 29%)住院。在射血分数降低的心衰-HFrEF 亚组中(n=1525),出院时接受心衰药物治疗的女性比例(49%接受 GDMT[指南指导的药物治疗]治疗的女性与男性 52%,P=0.197)没有显著差异。性别与 30 天内(30 天 OR[95%CI]为 0.89[0.71-1.11],P=0.304)或 1 年内(1 年 OR[95%CI]为 1.02[0.88-1.19],P=0.777)的再入院或死亡率也没有关联(院内 OR[95%CI]为 1.14[0.73-1.78],P=0.558;1 年 OR[95%CI]为 1.08[0.87-1.33],P=0.478)。当考虑基于左心室射血分数的不同心衰类别时,得到了相似的结果。
女性和男性表现出不同的临床特征。尽管这可能对医院路径(非心脏病学/心脏病学病房)和药物治疗方案产生影响,但性别本身似乎并不是临床决策的独立决定因素。此外,当考虑同质组时,女性并未被过度治疗。最后,女性性别与临床结局恶化无关。